Update shared on05 Sep 2025
Given the lack of material changes in both Chugai Pharmaceutical's revenue growth forecasts and future P/E ratio, analysts have maintained their consensus price target at ¥8,082.
What's in the News
- Orforglipron, an investigational GLP-1 receptor agonist, achieved positive topline results in two Phase 3 trials (ATTAIN-1 and ATTAIN-2), demonstrating significant weight loss, HbA1c reduction, and improvements in cardiometabolic risk factors, with a safety profile consistent with its drug class.
- Eli Lilly plans to submit orforglipron for weight management to global regulatory agencies by year-end; further Phase 3 results to be shared later this year.
- Chugai resolved to construct a new laboratory building ("UKX") at Ukima Site to enhance manufacturing process development for small and mid-size molecules and biopharmaceuticals, with an emphasis on R&D output, innovation, and environmental sustainability; this investment is not expected to affect FY2025 financial forecasts.
- Chugai and Gero PTE. LTD. announced a joint research and license agreement to develop antibody drugs for age-related diseases, leveraging Chugai's antibody engineering and Gero's AI target discovery platform; the deal includes milestone and royalty payments.
Valuation Changes
Summary of Valuation Changes for Chugai Pharmaceutical
- The Consensus Analyst Price Target remained effectively unchanged, at ¥8082.
- The Consensus Revenue Growth forecasts for Chugai Pharmaceutical remained effectively unchanged, moving only marginally from 4.9% per annum to 5.0% per annum.
- The Future P/E for Chugai Pharmaceutical remained effectively unchanged, moving only marginally from 29.55x to 29.51x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.